Intuitive Surgical Inc
What Are Intuitive Surgical’s Key Growth Drivers in 2019?
In the first quarter, Intuitive Surgical (ISRG) placed 235 da Vinci systems, a YoY (year-over-year) rise of 27.03%. However, its Systems revenue in the first quarter was $248 million, a YoY rise of 6%.
How Are Intuitive Surgical’s Revenues Trending in 2019?
According to its first-quarter earnings conference call, Intuitive Surgical reported a 27% YoY rise in total new system placements, while its installed base rose 13% YoY net of trade exam retirements. At the end of the first quarter, the company had an installed base of 5,110.
Druckenmiller Was Betting on These Top Names in Q4
Druckenmiller seemed to be positive on emerging markets, as the iShares MSCI Emerging Markets ETF (EEM) formed 3.8% of his portfolio at the end of the fourth quarter.
Do Analysts See Any Upside for Thermo Fisher Stock?
Of the 17 analysts covering Thermo Fisher Scientific (TMO), 14 recommend ” buy” or a higher rating, and three recommend “hold.”
Thermo Fisher Scientific’s Gross Margin Trends
In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.
How Intuitive Surgical Stock Has Performed in the Last Month
From a low of $376.92 on January 4, Intuitive Surgical (ISRG) stock rose to a high of $581.12 on October 1.
Intuitive Surgical Stock Has Seen Growth of 34% Year-to-Date
Intuitive Surgical’s stock price rose from $364.94 at the close of market on December 29, 2017, to $489.57 on November 23, 2018.
How TransEnterix Has Been Performing in November
In this series, we’ll explore TransEnterix’s financials, analyst recommendations, and valuation metrics.
Gauging Analysts’ Views for NovoCure Stock
Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.”
How Intuitive’s Bottom Line Is Expected to Look in Q3 2018
Intuitive Surgical’s (ISRG) cost of goods sold is expected to rise 16.82% to $265.76 million in the third quarter of 2018.
What to Expect from Intuitive Surgical’s Q3 2018 Earnings
Intuitive Surgical (ISRG) is expected to report its third-quarter earnings results on October 18.
TransEnterix Stock Rose 5.41% after Its Corporate Update
On October 1, TransEnterix stock closed at $5.64, which represents ~344.0% growth from its 52-week low of $1.27 on February 9.
What ViewRay’s Valuation Trend Indicates
In September, of the seven analysts covering ViewRay (VRAY), six have given its stock “buy” or higher ratings, and one analyst has given it a “sell” rating.
Analyzing the Performance of Danaher’s Dental Business
Danaher Corp.’s (DHR) enterprise value is $85.21 billion, and its enterprise-value-to-revenue ratio is 4.42.
How Quest Diagnostics Is Positioned in 2018
Quest Diagnostics generated revenues of $1.92 billion in the second quarter of 2018 as compared with $1.86 billion in the second quarter of 2017.
What’s the Upside Potential of Thermo Fisher Scientific Stock?
So far in 2018, Thermo Fisher Scientific (TMO) stock has generated double-digit returns for investors.
A Strong Business Model Bodes Well for Intuitive Surgical
Intuitive Surgical (ISRG) generates a major part of its revenue from the US market.
TransEnterix Stock Saw 18% Growth in Week Ended August 24
On August 24, TransEnterix (TRXC) stock closed at $5.37, which represents a ~6.13% growth from its prior day’s close of $5.06.
TransEnterix Expected to Report Solid Rise in Revenues in 2018
TransEnterix (TRXC) expects to sell three Senhance systems in Q3 2018.
What Analysts Recommend for TransEnterix and Peers in August 2018
Of the five analysts covering TransEnterix in August, one has recommended a “strong buy,” one has recommended a “buy,” and three have recommended a “hold.”
Why Most Analysts Are Bullish on NovoCure
NovoCure’s R&D expenses are expected to increase 47.06% from $9.37 million in Q2 2017 to $13.78 million in Q2 2018.
Why Goldman Sachs Thinks FB and NVIDIA Could Do Well in H2 2018
Year-to-date through July 5, Facebook has risen 11.7% and NVIDIA has risen 24.7%
Stryker’s Mako Robot Sales Momentum Continues to Fuel Growth
In 4Q17, the momentum in Stryker’s (SYK) Mako robot installations continued with total worldwide installations of 35 Mako robots.
Johnson & Johnson Advances in Robotics Surgery with Orthotaxy
On February 20, Johnson & Johnson (JNJ) announced the acquisition of Orthotaxy to develop its robot-assisted orthopedics surgery platform.
Intuitive Surgical: What’s Driving the Bull Run?
Leading surgical robotics player Intuitive Surgical (ISRG) is trading at all-time highs. The stock has been rising, returning 98% over the past year.
Intuitive Surgical’s Da Vinci Procedure Could Boost 2017 Results
According to Intuitive Surgical’s (ISRG) preliminary 4Q17 and 2017 results posted by the company on January 10, 2018, it expects to post da Vinci procedure growth of 17% in 4Q17.
Can Intuitive Surgical Beat Analyst Estimates Again in 4Q17?
On January 25, 2018, Intuitive Surgical (ISRG) is expected to announce its fiscal 4Q17 and fiscal 2017 earnings results. It’s expected to post strong results.
Will Varian Medical Systems’ Sales Decline Again in 1Q18?
According to Wall Street analysts’ estimates, Varian Medical Systems (VAR) will report revenues of $636.8 million in 1Q18, a YoY decline of 16.6%.
Analyst Recommendations for Varian Medical Systems before 1Q18
Varian Medical Systems (VAR) will announce its 1Q18 earnings results on January 24, 2018. It wants to establish itself as the leading cancer management company in the world.
Discussing Analysts’ Latest Recommendations on VAR Stock
Varian Medical Systems (VAR) is a better-aligned, leaner business with a strong market position after the spin-off of Varex Imaging (VREX) in January 2017.
How the Corporate Tax Rate Cut Could Affect R&D in the Medtech Industry
The repeal of the tax deduction for high medical expenses may reduce the number of taxpayers opting for costly medical technologies and services.
How the Medical Expense Tax Deduction Affects the Healthcare Industry
According to AARP, around 75% the population claiming these medical expense deductions from their income are 50 years or older.
Varian’s Latest Wall Street Recommendations: Mostly ‘Hold’
According to a recent Reuters survey, which included eight investment brokerage firms, six (or 75%) of them have recommended a “hold” for VAR stock.
Varian’s Long-Term Growth Strategy: Will It Drive 2018 Guidance?
Varian Medical Systems expects to see fiscal 2018 revenue growth in the range of 2%–4%. Its adjusted diluted EPS (earnings per share) for fiscal 2018 is expected to be $4.20–$4.32.
Varian Medical Systems’ Profitability Profile
In fiscal 4Q17, Varian Medical Systems (VAR) registered a gross profit margin of 42.3% of its total sales, representing a decline of 50 basis points.
Varian’s Performance by Geography and Future Growth Potential
Varian’s Oncology segment sales in the Americas rose 2%, whereas order growth in the region rose 1% in 4Q17.
Zimmer Biomet’s Plan to Revive Growth amid Supply Disruptions
Zimmer Biomet Holdings has laid down a dual sourcing strategy to resolve production issues at its Warsaw facility.
How Stryker Plans to Integrate Novadaq
Overview On September 1, 2017, Stryker completed the acquisition of Novadaq Technologies. The company announced the deal on June 19, 2017. For details on the announcement, read Stryker Acquires Novadaq, Enhances Its Endoscopic Offerings. That day, Stryker’s stock price fell, and the iShares Core S&P 500 ETF (IVV) rose ~1.4%. SYK makes up ~0.23% of IVV’s […]
Behind Intuitive Surgical’s Recent Stock Performance
ISRG stock has been trending higher and was trading at its 52-week high of $382.2 on October 27, 2017. Its closing price on October 26 was $372.3.
Why Intuitive Surgical Is Focusing on Imaging, Instruments, and Accessory Sales
In 3Q17, Intuitive Surgical reported ~$401 million in instruments and accessories revenues. Recurring revenues contributed ~68% of total sales.
How Intuitive Surgical Reported Such High Margins in 3Q17
Intuitive Surgical reported a gross profit margin of ~71.8% (of total sales) for 3Q17. This margin was lower, however, than the 73.1% it reported in 3Q16.
How Intuitive Surgical Is Expanding Its Da Vinci X Systems Worldwide
Intuitive Surgical’s (ISRG) Da Vinci X received early FDA approval in May 2017 and was given a CE Mark in Europe in April 2017.
Why Intuitive Surgical’s Da Vinci System Placements Looks Lumpy outside the US
In 3Q17, Intuitive Surgical (ISRG) registered system sales of ~$237 million, or ~15% higher on a YoY (year-over-year) basis.
Intuitive Surgical’s 3Q17 Revenue: Can It Beat the Estimates?
According to recent Wall Street analysts’ estimates, Intuitive Surgical is expected to report revenues of $753.2 million in 3Q17. That represents a YoY sales growth of 10.3%.
Intuitive Surgical’s High Valuation: Is the Stock Overvalued?
As of October 5, 2017, Intuitive Surgical’s (ISRG) forward PE (price-to-earnings) multiple is 120.3x, which is significantly higher than its peers and the industry average.
What Analysts Recommend for Intuitive Surgical
According to the latest rating recommendations in a Reuters survey comprised of 18 brokerage companies, 61.0% of the firms gave ISRG a “buy” rating, and 33.0% rated it a “hold.”
Intuitive Surgical Traded at a 52-Week High on October 5
Intuitive Surgical (ISRG), the leader in minimally invasive robotics surgery, has seen tremendous growth lately. It was trading at its 52-week high of $1,094.55 on October 5, 2017.
Why Most Analysts Recommend a ‘Buy’ for Varian Medical Systems
With its recent spin-off of Varex Imaging (VREX), Varian Medical Systems (VAR) has established itself as a focused cancer management medical technology company.
How Can BSX Improve Its Profitability Going Forward?
In 2Q17, Boston Scientific registered a gross profit margin of 72.8% of its total sales. That compares to 70.7% in 2Q16.
Wall Street’s Upbeat on Boston Scientific: Most Recommend a ‘Buy’
Wall Street analysts’ lowest one-year target price for Boston Scientific (BSX) stock is $24, representing a -11.4% maximum downside risk potential for the next year.
Strategic Investments Drive Intuitive Surgical’s Future Growth
Intuitive Surgical focused on accelerating its strategic investments in recent years. It wants to expand across low-cost and untapped markets.
Intuitive Surgical Plans to Expand in Europe and Asia
Although Intuitive Surgical leads the surgical robotics market, there are competitive threats from other major players in the market.
Analyzing Intuitive Surgical’s 2Q17 Results
On July 20, 2017, Intuitive Surgical (ISRG) released its 2Q17 earnings results. The company revenues and earnings beat analysts’ estimates.
Why Varian Medical Systems’ Profitability Is Improving
Varian Medical Systems’ profitability In 3Q17, Varian Medical Systems reported a gross margin of approximately 44.5%, representing an 18-basis-point improvement in the quarter. YTD (year-to-date), the margin has improved by around 138 basis points. In 3Q17, the company’s Oncology Systems business witnessed a gross margin improvement of 200 basis points to reach 48.1% of the segment’s total […]
Analysts’ Recommendations for Varian Medical Systems
With the spin-off of its Imaging Components business, Varian Medical Systems (VAR) is now more aligned with its core capabilities. In this series, we’ll discuss the company’s dynamics after the Varex spin-off.
How Intuitive Surgical Is Returning Value to Its Shareholders
As of March 31, 2017, Intuitive Surgical has cash, cash equivalents, and investments of about $ 3.1 billion.
What’s Driving Intuitive Surgical’s Recent Stock Performance?
As of July 13, 2017, Intuitive Surgical’s stock was trading ~35.0% above its 52-week low of $610.7 on December 7, 2016.
Can Intuitive Surgical’s Revenue Grow in 2017?
On July 20, 2017, Intuitive Surgical (ISRG) will announce its 2Q17 earnings. The company has exceeded analysts’ revenue estimates for the last several quarters.
What to Expect from Intuitive Surgical’s 2Q17 Earnings
Analysts estimate that Intuitive Surgical will post 2Q17 EPS (earnings per share) of ~$4.76. In 1Q17, Intuitive Surgical exceeded analysts’ diluted EPS estimate of $4.67.
What Wall Street Analysts Recommend for Intuitive Surgical
Intuitive Surgical (ISRG) is set to release its 2Q17 results on July 20, 2017.
Will Intuitive Surgical Stock Witness Continued Growth Momentum?
Intuitive Surgical (ISRG) has returned approximately 48.2% YTD (year-to-date), surpassing SPY as well as the Health Care Select Sector SPDR Fund (XLV) by enormous margins.
ISRG Expands across Low-Cost Markets with Da Vinci X Launch
On May 30, 2017, Intuitive Surgical (ISRG) announced that it received FDA (US Food and Drug Administration) approval of its new da Vinci X robotic surgical system.
Da Vinci Sp Could Boost ISRG Stock
Intuitive Surgical’s da Vinci Sp is the latest technological innovation in the company’s surgical systems.
Zimmer Biomet’s Inorganic Growth Strategy Is Helping Performance
In October 2016, Zimmer Biomet Holdings announced the acquisition of the RespondWell telerehabilitation platform.
What Drove Medtronic’s MITG Segment Growth?
Medtronic (MDT) reported ~$7.9 billion in worldwide revenues in fiscal 4Q17.
Key Highlights of Varian Medical Systems’ Fiscal 2Q17 Earnings
On April 26, 2016, Varian Medical Systems (VAR) released its 2Q17 earnings. VAR beat consensus estimates for revenues in 2Q17 by ~0.8% and reported in-line earnings per share.
What’s Intuitive Surgical’s Capital Allocation Strategy?
On December 13, 2016, Intuitive Surgical increased its authorized share repurchase program from $1.0 billion to $3.0 billion.
What to Expect from Intuitive Surgical’s 4Q16 Earnings
Intuitive Surgical expects about a 15.0% procedure growth in fiscal 2016, which is expected to boost the company’s earnings.
Here’s What’s Driving Medtronic’s MITG Segment
Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 2Q17, ~$2.5 billion came from Medtronic’s MITG segment, representing ~34% of the company’s total revenues.
Exploring SYK’s MAKO Robot Performance and Future Expectations
Stryker (SYK) has identified its need to differentiate its offerings in the competitive orthopedics market, which has undergone business model changes.
Particle Therapy Business Witnessed Continued Growth Momentum in 4Q16
Varian Medical Systems (VAR) registered revenues of $68.2 million in 4Q16, of which 7.5% came from the company’s oncology segment.
What Are the Key Drivers of Intuitive Surgical’s 3Q16 Growth?
Intuitive Surgical registered a YoY procedure growth of ~14% in 2Q16. Sales from da Vinci System outside the US also witnessed considerable growth.
International Flavors and Fragrances to Acquire David Michael
On September 13, International Flavors and Fragrances (IFF) announced that it entered into an agreement to acquire food flavor company David Michael.
Sector Composition of Principal LargeCap Growth Fund I in YTD 2016
Information technology is the largest invested sector by the Principal LargeCap Growth Fund I (PLGAX), comprising a little less than one-third of the portfolio.
Varian Medical Systems’ Oncology Devices Are Key to Sales Growth
Varian Medical Systems commands the majority share of the oncology device market in the United States.
Hernia Repair Should Drive Significant Growth for Intuitive Surgical
The benefits of robotic-assisted ventral hernia repair surgery were substantiated by study results released by Intuitive Surgical (ISRG) in early August 2016.
A Look at Zimmer Biomet’s Latest Valuation
After the release of its 2Q16 earnings results on July 28, 2016, Zimmer Biomet Holdings (ZBH) was trading at a forward price-to-earnings multiple in the range of 15.5x–16.2x.
Zimmer Biomet Focuses on Inorganic Growth Strategy
In July 2016, Zimmer Biomet completed the tender offer for outstanding shares of LDR Holding Corporation for $37 per share.
2Q16 Revenue Estimates for Intuitive Surgical
On July 19, 2016, Intuitive Surgical (ISRG) will announce its 2Q16 earnings. Wall Street has estimated the company’s 2Q16 revenues will come in at ~$640 million.
Analysts’ Latest Recommendations for Intuitive Surgical
The consensus 12-month target price for Intuitive Surgical (ISRG) is $684.50, which represents a potential rise of ~1.3%.
How Has Varian Medical Systems Progressed in Radiotherapy?
Varian Medical Systems (VAR) has an innovation-led product pipeline.
How Does Varian Medical Systems Compare to Peers on Valuation?
On June 16, 2016, Varian Medical Systems (VAR) was trading at a forward PE (price-to-earnings) ratio of ~17.7x.
Growth Strategies Driving Varian Medical Systems’ Revenue
Varian Medical Systems has ventured into the proton therapy business and has a huge product pipeline in this area. The company generated approximately $300 million through its proton therapy business in 2015.
Where Does Varian Medical Systems Get Most of Its Revenue?
Varian Medical Systems’ Imaging Components segment accounts for approximately 19% of the company’s total revenue. The segment reported a revenue decline of ~10% in 2015.
Medtronic: The New Entrant into the Robotic Surgery Business
Medtronic (MDT) is set to enter the robotic surgery market through a partnership with Mazor Robotics, an Israeli company. Mazor Robotics the Renaissance Guidance System used in spinal surgeries.
How PLGAX’s Portfolio Has Changed
The Principal LargeCap Growth Fund I Class A (PLGAX) invests at least 80% of its assets in equities of large-capitalization companies.
Boston Scientific to Present at Goldman Sachs Healthcare Conference
Boston Scientific (BSX) was the biggest gainer among the large caps of the iShares U.S. Medical Devices ETF (IHI).
How Has Intuitive Surgical’s Stock Price Been Performing?
Intuitive Surgical (ISRG) was trading at $621.4 as of May 17, 2016. It has a 50-day moving average of $623.9 and a 200-day moving average of $562.8.
Analyzing Intuitive Surgical’s R&D Strategy and Innovations
Intuitive Surgical is continuously enhancing its product offerings, enabling more efficient procedures through internal research and development (or R&D).
Understanding Intuitive Surgical’s Geographical Profile
Intuitive Surgical (ISRG) has established geographical growth as one its major growth drivers after procedure growth.
A Closer Look at Intuitive Surgical’s Business Strategy
Intuitive Surgical aims to include a larger patient population under its MIS treatments and to provide better surgery outcomes and lower recovery times.
Exploring Intuitive Surgical’s Sales Model
Intuitive Surgical follows a diversified sales strategy and doesn’t generate more than 10% of its revenue through any one customer.
How Is Procedure Growth Driving Intuitive Surgical’s Revenue?
The number of procedures performed using Intuitive Surgical’s da Vinci surgical system in 1Q16 rose by around 17% year-over-year.
What Does Intuitive Surgical’s Business Model Look Like?
Intuitive Surgical (ISRG) defines its business model as a “razor/razor blade” model. What does this mean?
Delving into the Nuances of the Da Vinci Surgical System
The da Vinci surgical system provides the benefits of minimally invasive surgery along with the precision and control of open surgery.
Company Overview: An Introduction to Intuitive Surgical
Intuitive Surgical is a pioneer of minimally invasive robotic surgery. It develops and manufactures da Vinci surgical systems and related instruments.
A Quick Look at the Principal LargeCap Growth Fund I
The Principal LargeCap Growth Fund I (PLGAX) invests at least 80% of its assets in equities of large-cap companies.
How Has Medical Device ETF IHI Performed?
The iShares US Medical Device ETF (IHI) has remained stable and has outperformed other healthcare and biotechnology ETFs in 2016.
How Reimbursement Models Impact the Medical Device Industry
Coverage, coding, and payment are essential elements to obtaining adequate reimbursement for a new medical device.
How Celgene Reacted to Positive Clinical Trials on October 26, 2015
Celgene rose by 2.95% and closed at $123.65, surpassing its 50- and 100-day moving average prices of $118.45 and $121.09.